

management strategies for Fire Island National Seashore for the next 15 to 20 years to support the protection of important natural resources and processes; significant recreation resources; cultural resources of national, state, and local significance; and residential communities.

The park is composed of two distinct units—the barrier island that runs parallel to the south shore of Long Island and the 613-acre William Floyd Estate situated on the south shore of Long Island near the east end of Fire Island. To address the specific needs of these two distinct units, the Draft GMP/EIS includes two sets of alternatives. One addresses park-wide alternatives for Fire Island National Seashore with a primary emphasis on the barrier island and includes a no-action alternative and two action alternatives. The other set of alternatives focuses specifically on the William Floyd Estate and includes a no-action and a single action alternative. The Draft GMP/EIS also incorporates plans for the Otis Pike High Dunes Fire Island Wilderness and includes a draft Wilderness Stewardship Plan for public review concurrent with the Draft GMP/EIS.

FOR FURTHER INFORMATION CONTACT:

Ellen Carlson, NPS/Northeast Region, 15 State Street, Boston, MA 02019. Phone: (617) 223-5048. Email: Fire_Island_GMP@nps.gov.

Dated: June 1, 2015.

Michael A. Caldwell,

Regional Director, Northeast Region, National Park Service.

[FR Doc. 2015-14927 Filed 6-16-15; 8:45 am]

BILLING CODE 4310-WV-P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701-TA-456 and 731-TA-1151-1152 (Review)]

Citric Acid and Certain Citrate Salts From Canada and China

Determination

On the basis of the record¹ developed in the subject five-year reviews, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930, that revocation of the countervailing duty order on citric acid and certain citrate salts from China and the antidumping duty orders on citric acid and certain citrate salts from China and Canada would be likely to lead to

continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

Background

The Commission, pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. 1675(c)), instituted these reviews on April 1, 2014 (79 FR 18311) and determined on July 7, 2014 that it would conduct full reviews (79 FR 42049, July 18, 2014). Notice of the scheduling of the Commission’s reviews and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** on November 14, 2014 (79 FR 68299). The hearing was held in Washington, DC, on March 26, 2015, and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission made these determinations pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on June 11, 2015. The views of the Commission are contained in USITC Publication 4538 (June 2015), entitled *Citric Acid and Certain Citrate Salts from Canada and China: Investigation Nos. 701-TA-456 and 731-TA-1151-1152 (Review)*.

By order of the Commission.

Issued: June 12, 2015.

Lisa R. Barton,

Secretary to the Commission.

[FR Doc. 2015-14863 Filed 6-16-15; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Siemens Healthcare Diagnostics, Inc.

ACTION: Notice of registration.

SUMMARY: Siemens Healthcare Diagnostics, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Siemens Healthcare Diagnostics, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated January 9, 2015, and published in

the **Federal Register** on January 26, 2015, 80 FR 3982, Siemens Healthcare Diagnostics, Inc., Attn: RA, 100 GBC Drive, Mailstop 514, Newark, Delaware 19702 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siemens Healthcare Diagnostics, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

Controlled substance	Schedule
Tetrahydrocannabinols (7370)	I
Ecgonine (9180)	II
Morphine (9300)	II
Thebaine (9333)	II

The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator controls which are DEA exempt products.

In reference to drug code 7370 the company plans to bulk manufacture a synthetic tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

Dated: June 11, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2015-14912 Filed 6-16-15; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-411F]

Adjusted Aggregate Production Quotas for Difenoxin, Diphenoxylate (for Conversion), and Marijuana

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order.

¹ The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).